NIH R01 · 2024
Role of glucocorticoid-suppression of preosteoclast PDGF-BB in skeletal angiogenesis
Project Summary Osteotoxic side effects of glucocorticoids, such as osteoporosis and osteonecrosis, limit clinical use. Children are a particularly vulnerable population as 30-50% of children on chronic glucocorticoids develop an osteotoxic side effect and there are no-FDA approved treatments for children. Although there have been extensive studies about glucocorticoid effects on the bone in the mature skeleton focusing largely on osteoclasts and osteoblasts, knowledge gaps still exist which in the growing skeleton. Bone, particularly growing bone, is highly vascularized. A unifying histological feature of osteoporosis, osteonecrosis, and impaired skeletal growth, is reduced bone…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.